JOURNAL OF PHARMACOLOGY AND
BIOMEDICINE
ISSN.2456-8244
The present study was undertaken to develop and evaluate a nanoparticle-based transdermal delivery system for venlafaxine to overcome these limitations and provide sustained drug release. Gelatin nanoparticles containing venlafaxine were prepared using the desolvation method with different crosslinking agents, namely glutaraldehyde, PVP, PEG 2000, and PEG 10000. The prepared nanoparticles were evaluated for particle size, percentage yield, drug entrapment efficiency, and in vitro drug release. Among all formulations, the glutaraldehyde-crosslinked formulation (F1) exhibited the smallest particle size (217.2 nm), highest drug entrapment efficiency (61.6%), and sustained drug release up to 24 h. The optimized nanoparticles were further incorporated into transdermal patches prepared by the solvent casting method using HPMC and Eudragit polymers. The patches were evaluated for physicochemical characteristics including thickness, weight variation, drug content, surface pH, folding endurance, and in vitro permeation. All formulations demonstrated satisfactory mechanical properties, uniform drug distribution, and acceptable surface pH. In vitro permeation studies revealed sustained drug release over 24 h, with formulation P4 showing the highest cumulative drug release (87.33%). The findings suggest that nanoparticle-loaded transdermal patches can effectively enhance the controlled delivery of venlafaxine, potentially improving bioavailability, reducing dosing frequency, and increasing patient compliance. Thus, the developed nanoparticle-based transdermal system represents a promising alternative to conventional oral venlafaxine therapy.
NAMES:
ONLINE ISSN:24568244
Keywords: Venlafaxine; Gelatin Nanoparticles; Transdermal Drug Delivery; Sustained Release; Nanoparticle- Loaded Patch
DOI:
1. https://go.drugbank.com/drugs/DB00285; assessed on 19/04/2026
2. https://pubchem.ncbi.nlm.nih.gov/compound/Venlafaxine; assessed on 19/04/2026
3. Pastore MN, Kalia YN, Horstmann M, Roberts MS. Transdermal patches: history, development and
pharmacology. British Journal of pharmacology. 2015; 172: 2179-2209
4. Ghodke SD, Kalamkar VM, Musmade SR, Jori DK, Chaudhari ML. Formulation and evaluation of
transdermal patch for pain management. Int J Creative Res Thoughts. 2025;13(5):837-846.
5. Karnakoti A, Borade A, Birajdar P, Bodke V, Dagale M, Badekar R. Formulation and evaluation of
transdermal patch. Int J Sci Res Technol. 2025;2(2):77-86.
6. Khare R, Tripathi D, Lal M, Kondalkar A. Formulation and evaluation of transdermal patches of etodolac
for topical application. Journal of Pharmaology and Biomedicine. 2022; 7(2): 589-597
7. KB, Hoff DJ, Lahren TJ, Mount DR, Squillace AJ, Burkhard LP. Estimating n-octanol-water partition
coefficients for neutral highly hydrophobic chemicals using measured n-butanol-water partition coefficients.
Chemosphere. 2019; 218: 616-623.
8. Sowmya C, Reddy YP, Kiran Kumar M, Santhosh Raja M. Development and validation of
spectrophotometric method for the estimation of venlafaxine in bulk and formulations. International Journal
of Chemical Sciences. 2011; 9(1): 52-58
9. Elzoghby AO. Gelatin-based nanoparticles as drug and gene delivery systems: Reviewing three decades of
research. Journal of controlled release, 2013; 172: 1075-1091.
10. Sailaja KA, Amareshwar P, Chakravarty P. Different techniques used for the preparation of nanoparticles
using natural polymers and their application. International Journal of Pharmacy and Pharmaceutical Sciences.
2011;3(2): 45-50.
11. Trivedi D, Goyal A. Formulation and evaluation of transdermal patches containing dexketoprofen
trometamol. International Journal of Pharmaceutical Chemistry and Analysis. 2020;7(2): 87–97
12. Gupta A, Mehta P. Formulation and evaluation of transdermal patches of Lamotrigine. Journal of
Pharmacology and Biomedicine. 2021; 5(1): 242-248
13. Sheth NS, Mistry RB. Formulation and evaluation of transdermal patches and to study permeation
enhancement effect of eugenol. J. Appl. Pharm. Sci. 2011; 1 (3); 96-101
14. Mutalic S, Udupa N. Glibenclamide transdermal patches: physicochemical, pharmacodynamic, and
pharmacokinetic evaluations. Journal of Pharmaceutical Sciences 2004; 93: 1577-1594.